Your browser doesn't support javascript.
loading
Evolution of COVID-19 symptoms during the first 9 months after illness onset
Elke Wynberg; Hugo van Willigen; Maartje Dijkstra; Anders Boyd; Neeltje A. Kootstra; Joost G. van den Aardweg; Marit J. van Gils; Amy Matser; Marije R. de Wit; Tjalling Leenstra; Godelieve J. de Bree; Menno D. de Jong; Maria Prins.
Afiliação
  • Elke Wynberg; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands
  • Hugo van Willigen; Department of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, th
  • Maartje Dijkstra; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands
  • Anders Boyd; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands
  • Neeltje A. Kootstra; Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
  • Joost G. van den Aardweg; Department of Pulmonology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
  • Marit J. van Gils; Department of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, th
  • Amy Matser; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands
  • Marije R. de Wit; Department of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
  • Tjalling Leenstra; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands
  • Godelieve J. de Bree; Department of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
  • Menno D. de Jong; Department of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, th
  • Maria Prins; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands
Preprint em Inglês | medRxiv | ID: ppmedrxiv-21256710
Artigo de periódico
Um artigo publicado em periódico científico está disponível e provavelmente é baseado neste preprint, por meio do reconhecimento de similaridade realizado por uma máquina. A confirmação humana ainda está pendente.
Ver artigo de periódico
ABSTRACT
BackgroundFew longitudinal data on COVID-19 symptoms across the full spectrum of disease severity are available. We evaluated symptom onset, severity and recovery up to nine months after illness onset. MethodsThe RECoVERED Study is a prospective cohort study based in Amsterdam, the Netherlands. Participants aged>18 years were recruited following SARS-CoV-2 diagnosis via the local Public Health Service and from hospitals. Standardised symptom questionnaires were completed at recruitment, at one week and month after recruitment, and monthly thereafter. Clinical severity was defined according to WHO criteria. Kaplan-Meier methods were used to compare time from illness onset to symptom recovery, by clinical severity. We examined determinants of time to recovery using multivariable Cox proportional hazards models. ResultsBetween 11 May 2020 and 31 January 2021, 301 COVID-19 patients (167[55%] male) were recruited, of whom 99/301(32.9%) had mild, 140/301(46.5%) moderate, 30/301(10.0%) severe and 32/301(10.6%) critical disease. The proportion of symptomatic participants who reported at least one persistent symptom at 12 weeks after illness onset was greater in those with severe/critical disease (81.7%[95%CI=68.7-89.7%]) compared to those with mild or moderate disease (33.0%[95%CI=23.0-43.3%] and 63.8%[95%CI=54.8-71.5%]). Even at nine months after illness onset, almost half of all participants (42.1%[95%CI=35.6-48.5]) overall continued to report [≥]1 symptom. Recovery was slower in participants with BMI[≥]30kg/m2 (HR 0.51[95%CI=0.30-0.87]) compared to those with BMI<25kg/m2, after adjusting for age, sex and number of comorbidities. ConclusionsCOVID-19 symptoms persisted for nine months after illness onset, even in those with mild disease. Obesity was the most important determinant of speed of recovery from symptoms.
Licença
cc_no
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Cohort_studies / Experimental_studies / Estudo observacional / Estudo prognóstico Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Cohort_studies / Experimental_studies / Estudo observacional / Estudo prognóstico Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
...